High Court Won’t Consider Obviousness Of Oxycontin Patent Claims
WASHINGTON, D.C. — The U.S. Supreme Court on Oct. 6 rejected a petition for a writ of certiorari from Purdue Pharma LP and related entities, which told the justices that the...To view the full article, register now.
Already a subscriber? Click here to view full article